This MedLibrary.org supplementary page on Famotidine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Famotidine
|
|
| Systematic (IUPAC) name | |
| 2-[4-[2-(amino-sulfamoylimino-methyl) ethylsulfanylmethyl]-1,3-thiazol-2-yl]guanidine |
|
| Identifiers | |
| CAS number | |
| ATC code | A02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C8H15N7O2S3 |
| Mol. mass | 337.449 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20–66% |
| Protein binding | 10–28% |
| Metabolism | hepatic-less than 30% |
| Half life | 2.5-4 hours (clinical half-life 8-12 hours) |
| Excretion | Principally excreted unchanged in urine |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status |
S3/S4 (Au), POM/OTC (UK), |
| Routes | Oral, IV |
Famotidine (INN) (pronounced /fəˈmɒtɪdiːn/) is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by J&J/Merck under the trade names Pepcidine and Pepcid.
Clinical use
Main article: H2-receptor antagonist
Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States, preparations of 10 mg and 20 mg tablets, sometimes in combination with a more traditional antacid, are available OTC. Larger doses still require a prescription.
Famotidine is given to surgery patients before operations to prevent post-operation nausea and to reduce the risk of aspiration pneumonitis.
History and development
Famotidine was developed by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole-ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 30 times more active than cimetidine.
It was first marketed in 1985. Pepcid RPD orally-disintegrating tablets (that are not swallowed) was released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States, a product called Pepcid Complete is available that combines famotidine with an antacid in a chewable tablet to ameliorate the relatively slow onset of effects. In the UK, this product is known as Pepcidtwo.
|
||||||||||||||
Wikipedia content modification information:
- This page was last modified on 25 June 2008, at 01:31.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Famotidine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.